accumulating data now highlight an overlap between these risk loci and cellspecific enhancer elements that is maximal in CD4+ lymphocytes, followed by B lymphocytes Objectives: Seeking insight into genetic risk mechanisms, we conducted and compared expression quantitative trait locus (eQTL) analyses of risk loci in CD4+ T cells and B cells from carefully phenotyped early arthritis patients naïve to therapeutic immunomodulation. Methods: 254 patients donated RNA and DNA from purified B and/or CD4+ T-cells within 4 hours of blood draw. Genotyping and global gene expression measurement were carried out using the Illumina Human CoreExome array and either HT12v4 or WG6v3 BeadChip arrays respectively. Variants in linkage disequilibrium (LD) with 101 confirmed non-HLA RA-SNPs (r 2 >0.8) were analysed, seeking evidence of cis-or trans-eQTLs according to whether associated probes were or were not within 4MB of these LD blocks. Results: Genes subject to cis eQTL effects common to both CD4+ and Blymphocytes at RA risk loci were FADS1, FADS2, BLK, FCRL3, ORMDL3 and GSDMB. At the 8p23 BLK-FAM167A locus, we found adjacent genes subject to eQTLs whose activity differed markedly between cell types, the FAM167A effect displaying striking B-lymphocyte specificity. By contrast, cis eQTLs acting on METTL21B, IKZF3, and PADI4 were unique to CD4+ lymphocytes, the latter two of these being identified for the first time in this cell subset. No trans eQTLs approached experiment-wide significance, and linear modelling did not identify a significant influence of biological co-variates (diagnosis, systemic inflammation, age) upon eQTL effect sizes. Conclusions: Our findings refine understanding of candidate causal genes in RA pathogenesis, providing an important platform from which downstream functional studies may be prioritised and directed towards particular cell types. Background: The identification of genetic variants that differentiate PsA from psoriasis has the potential to help us understand the underlying biological pathways that lead to the development of PsA. Associations to genetic variants within the major histocompatibility complex (MHC), in particular to HLA-C*0602, increase risk of both PsA and psoriasis when compared to control populations. However direct comparisons of PsA to psoriasis have led to paradoxical associations where HLA-C*0602 has been reported to be protective of PsA. In addition HLA-C*0602 has been reported to be associated with age of onset of psoriasis. A more recent study has reported the amino acid at position 45 of the HLA-B protein as the most important factor for differentiating PsA from psoriasis. Objectives: Here we perform a cross phenotype association analysis in an attempt to identify genetic variants in the MHC that differentiate PsA from psoriasis in a large collection of PsA patients and psoriasis patients screened for the absence of PsA. Methods: A total of 1069 patients with psoriasis and 981 patients with PsA from the UK were genotyped using either the Illumina Immunochip or the Illumina OmniExpress genotyping arrays. SNPs, amino acids and classical HLA alleles were imputed using SNP2HLA. Logistic regression was used to compare the imputed dosage of MHC markers between PsA and psoriasis. All analyses were repeated using age of psoriasis onset as an additional covariate. Results: The most significant association when comparing PsA to psoriasis was to HLA-C*0602 (p=4.17x10 -15 ) with a protective effect for PsA (OR 0.52, CI 0.44:0.61). HLA-C*0602 was found to be significantly associated with a younger age of psoriasis onset (p=1.51x10
THU0004 CROSS PHENOTYPE ASSOCIATION MAPPING OF THE MHC IDENTIFIES GENETIC VARIANTS THAT DIFFERENTIATE PSORIATIC ARTHRITIS FROM PSORIASIS
Background: The identification of genetic variants that differentiate PsA from psoriasis has the potential to help us understand the underlying biological pathways that lead to the development of PsA. Associations to genetic variants within the major histocompatibility complex (MHC), in particular to HLA-C*0602, increase risk of both PsA and psoriasis when compared to control populations. However direct comparisons of PsA to psoriasis have led to paradoxical associations where HLA-C*0602 has been reported to be protective of PsA. In addition HLA-C*0602 has been reported to be associated with age of onset of psoriasis. A more recent study has reported the amino acid at position 45 of the HLA-B protein as the most important factor for differentiating PsA from psoriasis. Objectives: Here we perform a cross phenotype association analysis in an attempt to identify genetic variants in the MHC that differentiate PsA from psoriasis in a large collection of PsA patients and psoriasis patients screened for the absence of PsA. Methods: A total of 1069 patients with psoriasis and 981 patients with PsA from the UK were genotyped using either the Illumina Immunochip or the Illumina OmniExpress genotyping arrays. SNPs, amino acids and classical HLA alleles were imputed using SNP2HLA. Logistic regression was used to compare the imputed dosage of MHC markers between PsA and psoriasis. All analyses were repeated using age of psoriasis onset as an additional covariate. Results: The most significant association when comparing PsA to psoriasis was to HLA-C*0602 (p=4.17x10 -15 ) with a protective effect for PsA (OR 0.52, CI 0.44:0.61). HLA-C*0602 was found to be significantly associated with a younger age of psoriasis onset (p=1.51x10
-60 ) where the median age of onset in years for carriage is 22 compared to 33 for non-carriage. We observed a difference in the median age of psoriasis onset in years between the PsA and psoriasis study subgroups (34 vs. 21), highlighting the potential for bias at markers associated with age of psoriasis onset. When controlling for the age of psoriasis onset in the analyses we observed no association of PsA to HLA-C*0602 (p=0.07) and the most significant association was to the amino acid at position 97 of HLA-B (p=1.54x10 -9 ) where the presence of asparagine or serine residue increased risk of PsA. Asparagine at position 97 of HLA-B defines the HLA-B*2705 allele. Conclusions: Comparing PsA to psoriasis we show HLA-C*0602 confers no effect, either risk or protective, for PsA after correction for age of psoriasis onset. The results suggest that the previously observed protective effect of HLA-C*0602 could be due to confounding due to a younger age of psoriasis onset in the psoriasis subgroup. When accounting for age of psoriasis onset, the primary association conferring risk for PsA in patients with psoriasis is to HLA-B amino-acid 97 where an asparagine residue defines the HLA-B*2705 allele. In addition, this amino acid has been reported as the largest genetic effect for ankylosing spondylitis thereby refining the genetic overlap between these two spondyloarthropathies. Background: Since 1973, the association of HLA-B27 and spondyloarthritis (SpA) is well known, however in Colombian population it is present in only 40% of patients and HLA-B15 is present almost in 25%. A mechanism of polygenic mechanism has been proposed as an explanation for the development of SpA. Endoplasmic reticulum aminopeptidase (ERAP) genes 1 and 2 have been implicated. ERAP1 is strongly associated with HLA-B27 positive patients and ankylosing spondylitis, but not with ERAP2 Objectives: To determine the association between ERAP polymorphisms and HLA-B27 or HLA-B15 positive SpA patients Methods: 178 patients with SpA according to ASAS criteria were included in the study. HLA typing was performed by the PCR technique using the Biorad ® HLA-SSP plates. The polymorphisms were determined by the RT-PCR technique using Roche ® probes for ERAP1 rs27044, rs17482078, rs10050860, and rs30187. For ERAP2 the probes used were rs2910686, rs2248374 and rs2549782. The 
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